Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Autolus Therapeutics Plc ADR (NQ: AUTL )

6.533 USD -0.167 (-2.50%)
Streaming Delayed Price Updated: 11:22 AM EDT, Sep 20, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 94,091
Open 6.450
Bid (Size) 6.500 (4)
Ask (Size) 6.540 (4)
Prev. Close 6.700
Today's Range 6.400 - 6.640
52wk Range 4.600 - 14.22
Shares Outstanding 52,346,231
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK
- Allowing global commercial launch capacity for obe-cel (AUTO1) 
From GlobeNewswire News Releases
Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors
From GlobeNewswire News Releases

Performance

YTD
-30.21%
-30.21%
1 Month
+15.83%
+15.83%
3 Month
-8.51%
-8.51%
6 Month
-4.21%
-4.21%
1 Year
-51.39%
-51.39%

More News

Read More
Autolus Therapeutics to participate in upcoming virtual investor conferences
From GlobeNewswire News Releases
Autolus Therapeutics announces publication of obe-cel (AUTO1) Phase 1 ALLCAR19 data in adults with relapsed/ refractory B-ALL in Journal of Clinical Oncology
From GlobeNewswire News Releases
Autolus Therapeutics Announces Promising Innovative Medicine (PIM) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL
From GlobeNewswire News Releases
Autolus Therapeutics Reports Second Quarter 2021 Financial Results and Operational Progress
From GlobeNewswire News Releases
Novaremed Expands its Pipeline of Non-opioid Treatment Candidates for Chronic Pain Indications Through Acquisition of Metys Pharmaceuticals
From Business Wire News Releases
Autolus and Moderna sign Option and License Agreement for access to proprietary targeting technology from Autolus
From GlobeNewswire News Releases
Autolus Announces Appointment of Edgar Braendle, M.D., Ph.D., as Chief Development Officer
From GlobeNewswire News Releases
Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William Blair Biotech Focus Conference 2021 on July 14, 2021
From GlobeNewswire News Releases
Autolus Therapeutics Announces Innovation Licensing and Access Pathway (ILAP) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.